Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19

Komissarov et al., medRxiv, doi:10.1101/2020.06.30.20143289
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Viral load -25% Improvement Relative Risk HCQ for COVID-19  Komissarov et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 36 patients in Russia Worse viral load with HCQ (not stat. sig., p=0.45) c19hcq.org Komissarov et al., medRxiv, June 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 control and 33 patients, showing no significant differences (significant reduction in viral load is seen in both groups).
The groups are not comparable, with significant differences seen between hospitalized and non-hospitalized patients. 9 of 10 hospitalized patients were in the HCQ group and only one in the control group. 2 additional control patients were added between the first and second version of this preprint (including the only hospitalized control patient).
risk of viral load, 25.0% higher, RR 1.25, p = 0.45, treatment 26, control 10.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Komissarov et al., 30 Jun 2020, retrospective, Russia, preprint, 8 authors.
This PaperHCQAll
Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19
Alexey Komissarov, Ivan Molodtsov, Oxana Ivanova, Elena Maryukhnich, Svetlana Kudryavtseva, Alexey Mazus, Evgeniy Nikonov, MD Elena Vasilieva
doi:10.1101/2020.06.30.20143289
Due to the constantly growing numbers of COVID-19 infections and death cases attempts were undertaken to find drugs with anti SARS-CoV-2 activity among ones already approved for other pathologies. In the framework of such attempts, in a number of in vitro, as well as in vivo, models it was shown that hydroxychloroquine (HCQ) has an effect against SARS-CoV-2. While there was not enough clinical data to support the use of HCQ, several countries including Russia have included HCQ in treatment protocols for infected patients and for prophylactic. Here, we evaluated the SARS-CoV-2 RNA in nasopharynx swabs from infected patients in mild conditions and compared the viral RNA load dynamics between patients receiving HCQ and control group without antiviral pharmacological therapy. We found statistically significant relationship between maximal RNA quantity and patients' deteriorating medical conditions, as well as confirmed the arterial hypertension to be a risk factor for people with COVID-19. However, we showed that HCQ therapy neither shortened the viral shedding period nor reduced the virus RNA load.
References
Hashem, Therapeutic use of chloroquine and hydroxychloroquine in covid-19 and other viral infections: A narrative review. Travel medicine and infectious disease
Huang, Covid-19 patients with hypertension have more severe disease: A multicenter retrospective observational study, Hypertension Research
Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting sars-cov-2 infection in vitro, Cell discovery
Pan, Zhang, Yang, Poon, Wang, Viral load of sars-cov-2 in clinical samples, The Lancet Infectious Diseases
Yao, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Yu, Quantitative detection and viral load analysis of sars-cov-2 in infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Zhou, Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, china: A retrospective cohort study, The Lancet
Zou, Sars-cov-2 viral load in upper respiratory specimens of infected patients, New England Journal of Medicine
{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T23:10:30Z', 'timestamp': 1709334630492}, 'posted': {'date-parts': [[2020, 7, 3]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 8, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 9, 16]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Due to the constantly growing numbers of COVID-19 ' 'infections and death cases attempts were undertaken to find drugs with anti SARS-CoV-2 ' 'activity among ones already approved for other pathologies. In the framework of such ' 'attempts, in a number of in vitro, as well as in vivo, models it was shown that ' 'hydroxychloroquine (HCQ) has an effect against SARS-CoV-2. While there was not enough ' 'clinical data to support the use of HCQ, several countries including Russia have included HCQ ' 'in treatment protocols for infected patients and for prophylactic. Here, we evaluated the ' 'SARS-CoV-2 RNA in nasopharynx swabs from infected patients in mild conditions and compared ' 'the viral RNA load dynamics between patients receiving HCQ and control group without ' 'antiviral pharmacological therapy. We found statistically significant relationship between ' 'maximal RNA quantity and patients’ deteriorating medical conditions, as well as confirmed the ' 'arterial hypertension to be a risk factor for people with COVID-19. However, we showed that ' 'HCQ therapy neither shortened the viral shedding period nor reduced the virus RNA ' 'load.</jats:p>', 'DOI': '10.1101/2020.06.30.20143289', 'type': 'posted-content', 'created': {'date-parts': [[2020, 7, 3]], 'date-time': '2020-07-03T16:42:12Z', 'timestamp': 1593794532000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of ' 'COVID-19', 'prefix': '10.1101', 'author': [ {'given': 'Alexey', 'family': 'Komissarov', 'sequence': 'first', 'affiliation': []}, {'given': 'Ivan', 'family': 'Molodtsov', 'sequence': 'additional', 'affiliation': []}, {'given': 'Oxana', 'family': 'Ivanova', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elena', 'family': 'Maryukhnich', 'sequence': 'additional', 'affiliation': []}, {'given': 'Svetlana', 'family': 'Kudryavtseva', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexey', 'family': 'Mazus', 'sequence': 'additional', 'affiliation': []}, {'given': 'Evgeniy', 'family': 'Nikonov', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elena', 'family': 'Vasilieva', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021021207400923000_2020.06.30.20143289v2.1', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (sars-cov-2)', 'volume': '71', 'year': '2020', 'journal-title': 'Clinical infectious diseases: an official publication of the Infectious ' 'Diseases Society of America.'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.2', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting sars-cov-2 infection in vitro', 'volume': '6', 'year': '2020', 'journal-title': 'Cell discovery.'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.3', 'doi-asserted-by': 'crossref', 'first-page': '101735', 'DOI': '10.1016/j.tmaid.2020.101735', 'article-title': 'Therapeutic use of chloroquine and hydroxychloroquine in covid-19 and ' 'other viral infections: A narrative review', 'volume': '35', 'year': '2020', 'journal-title': 'Travel medicine and infectious disease.'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30113-4'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2001737'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.6', 'doi-asserted-by': 'crossref', 'first-page': '793', 'DOI': '10.1093/cid/ciaa345', 'article-title': 'Quantitative detection and viral load analysis of sars-cov-2 in ' 'infected patients', 'volume': '71', 'year': '2020', 'journal-title': 'Clinical infectious diseases: an official publication of the Infectious ' 'Diseases Society of America.'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/SO140-6736(20)30566-3'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.8', 'doi-asserted-by': 'crossref', 'first-page': '824', 'DOI': '10.1038/s41440-020-0485-2', 'article-title': 'Covid-19 patients with hypertension have more severe disease: A ' 'multicenter retrospective observational study', 'volume': '43', 'year': '2020', 'journal-title': 'Hypertension Research.'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.06.30.20143289', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 12, 15]], 'date-time': '2021-12-15T15:07:17Z', 'timestamp': 1639580837000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.06.30.20143289'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 7, 3]]}, 'references-count': 8, 'URL': 'http://dx.doi.org/10.1101/2020.06.30.20143289', 'relation': { 'is-preprint-of': [ { 'id-type': 'doi', 'id': '10.1371/journal.pone.0246396', 'asserted-by': 'subject'}]}, 'published': {'date-parts': [[2020, 7, 3]]}, 'subtype': 'preprint'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit